172 related articles for article (PubMed ID: 24234258)
1. A pooled analysis of the ERCC2 Asp312Asn polymorphism and esophageal cancer susceptibility.
Wen F; Zhao Z; Liu C; Yin Q; Weng J; Wang Y; Ma Y
Tumour Biol; 2014 Apr; 35(4):2959-65. PubMed ID: 24234258
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism of ERCC2 Asp312Asn with lung cancer risk: evidence from 20,101 subjects.
Tan X; Wang Y; Shi L; Xian L; Guo J; Liang G; Chen M
Genet Test Mol Biomarkers; 2014 Jan; 18(1):50-6. PubMed ID: 24083550
[TBL] [Abstract][Full Text] [Related]
3. Xeroderma pigmentosum group D polymorphisms and esophageal cancer susceptibility: a meta-analysis based on case-control studies.
Yang R; Zhang C; Malik A; Shen ZD; Hu J; Wu YH
World J Gastroenterol; 2014 Nov; 20(44):16765-73. PubMed ID: 25469049
[TBL] [Abstract][Full Text] [Related]
4. Association between the ERCC2 Asp312Asn polymorphism and risk of cancer.
Xiao F; Pu J; Wen Q; Huang Q; Zhang Q; Huang B; Huang S; Lan A; Zhang Y; Li J; Zhao D; Shen J; Wu H; He Y; Li H; Yang X
Oncotarget; 2017 Jul; 8(29):48488-48506. PubMed ID: 28489582
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of xeroderma pigmentosum group D gene Asp312Asn and Lys751Gln and susceptibility to prostate cancer: a systematic review and meta-analysis.
Ma Q; Qi C; Tie C; Guo Z
Gene; 2013 Nov; 530(2):309-14. PubMed ID: 23973729
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive assessment of associations between ERCC2 Lys751Gln/Asp312Asn polymorphisms and risk of non- Hodgkin lymphoma.
Zhou JY; He LW; Liu J; Yu HL; Wei M; Ma WL; Shi R
Asian Pac J Cancer Prev; 2014; 15(21):9347-53. PubMed ID: 25422223
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of excision repair cross-complementing group 2 gene Lys751Gln and Asp312Asn polymorphisms in melanoma risk.
Zhou X; Zeng Y; Jiang H; Xia L; Liu C
Melanoma Res; 2018 Aug; 28(4):311-318. PubMed ID: 29768284
[TBL] [Abstract][Full Text] [Related]
8. Association between XPD Asp312Asn polymorphism and esophageal cancer susceptibility: a meta-analysis.
Duan XL; Gong H; Zeng XT; Ni XB; Yan Y; Chen W; Liu GL
Asian Pac J Cancer Prev; 2012; 13(7):3299-303. PubMed ID: 22994751
[TBL] [Abstract][Full Text] [Related]
9. ERCC2 Lys751Gln and Asp312Asn polymorphisms and gastric cancer risk: a meta-analysis.
Chen B; Zhou Y; Yang P; Wu XT
J Cancer Res Clin Oncol; 2011 Jun; 137(6):939-46. PubMed ID: 20981556
[TBL] [Abstract][Full Text] [Related]
10. XPD Lys751Gln and Asp312Asn polymorphisms and gastric cancer susceptibility: a meta-analysis of case-control studies.
Yin QH; Liu C; Hu JB; Meng RR; Li L; Wang YJ
Asian Pac J Cancer Prev; 2013; 14(1):231-6. PubMed ID: 23534729
[TBL] [Abstract][Full Text] [Related]
11. Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis.
Li SX; Dai QS; Chen SX; Zhang SD; Liao XY; Deng X; Chi HB; Li FJ; Zhu JH; Jiang YY
Tumour Biol; 2014 Apr; 35(4):3905-15. PubMed ID: 24347488
[TBL] [Abstract][Full Text] [Related]
12. Complex association between ERCC2 gene polymorphisms, gender, smoking and the susceptibility to bladder cancer: a meta-analysis.
Wu Y; Yang Y
Tumour Biol; 2014 Jun; 35(6):5245-57. PubMed ID: 24504678
[TBL] [Abstract][Full Text] [Related]
13. The association between ERCC2 Asp312Asn polymorphism and breast cancer risk: a meta-analysis involving 22,766 subjects.
Yao L; Qiu LX; Yu L; Yang Z; Yu XJ; Zhong Y; Hu XC; Yu L
Breast Cancer Res Treat; 2010 Aug; 123(1):227-31. PubMed ID: 20127278
[TBL] [Abstract][Full Text] [Related]
14. XPD Lys751Gln polymorphism and esophageal cancer risk: a meta-analysis involving 2288 cases and 4096 controls.
Yuan L; Cui D; Zhao EJ; Jia CZ; Wang LD; Lu WQ
World J Gastroenterol; 2011 May; 17(18):2343-8. PubMed ID: 21633601
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms in DNA repair genes and their association with risk of cervical cancer: A systematic review and meta-analysis.
Shao X; Yang X; Liu Y; Song Q; Pan X; Chen W; Jiang W; Xu D; Song Y; Chen R
J Obstet Gynaecol Res; 2022 Sep; 48(9):2405-2418. PubMed ID: 35732591
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer.
Pabalan N; Francisco-Pabalan O; Sung L; Jarjanazi H; Ozcelik H
Breast Cancer Res Treat; 2010 Nov; 124(2):531-41. PubMed ID: 20379847
[TBL] [Abstract][Full Text] [Related]
17. XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: a meta-analysis.
Yan Y; Liang H; Light M; Li T; Deng Y; Li M; Li S; Qin X
Tumour Biol; 2014 Mar; 35(3):1907-15. PubMed ID: 24101192
[TBL] [Abstract][Full Text] [Related]
18. Association Studies of ERCC2 rs13181 Polymorphism with Pancreatic Cancer Susceptibility.
Shao T; Kou J
Crit Rev Eukaryot Gene Expr; 2021; 31(2):17-23. PubMed ID: 34347976
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive assessment of the association of ERCC2 Lys751Gln polymorphism with susceptibility to cutaneous melanoma.
Dong Y; Zhuang L; Ma W
Tumour Biol; 2013 Apr; 34(2):1155-60. PubMed ID: 23494240
[TBL] [Abstract][Full Text] [Related]
20. The effect of XPD/ERCC2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis.
Xue H; Lu Y; Lin B; Chen J; Tang F; Huang G
PLoS One; 2012; 7(9):e43431. PubMed ID: 23028453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
